JP7829230B2 - 多能性幹細胞からアストロサイトを製造する方法 - Google Patents

多能性幹細胞からアストロサイトを製造する方法

Info

Publication number
JP7829230B2
JP7829230B2 JP2022562230A JP2022562230A JP7829230B2 JP 7829230 B2 JP7829230 B2 JP 7829230B2 JP 2022562230 A JP2022562230 A JP 2022562230A JP 2022562230 A JP2022562230 A JP 2022562230A JP 7829230 B2 JP7829230 B2 JP 7829230B2
Authority
JP
Japan
Prior art keywords
pluripotent stem
cells
stem cells
neurog2
astrocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022562230A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022102787A5 (https=
JPWO2022102787A1 (https=
Inventor
治久 井上
孝之 近藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Publication of JPWO2022102787A1 publication Critical patent/JPWO2022102787A1/ja
Publication of JPWO2022102787A5 publication Critical patent/JPWO2022102787A5/ja
Application granted granted Critical
Publication of JP7829230B2 publication Critical patent/JP7829230B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
JP2022562230A 2020-11-16 2021-11-16 多能性幹細胞からアストロサイトを製造する方法 Active JP7829230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020190575 2020-11-16
JP2020190575 2020-11-16
PCT/JP2021/042096 WO2022102787A1 (ja) 2020-11-16 2021-11-16 多能性幹細胞からアストロサイトを製造する方法

Publications (3)

Publication Number Publication Date
JPWO2022102787A1 JPWO2022102787A1 (https=) 2022-05-19
JPWO2022102787A5 JPWO2022102787A5 (https=) 2024-08-26
JP7829230B2 true JP7829230B2 (ja) 2026-03-13

Family

ID=81601395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562230A Active JP7829230B2 (ja) 2020-11-16 2021-11-16 多能性幹細胞からアストロサイトを製造する方法

Country Status (2)

Country Link
JP (1) JP7829230B2 (https=)
WO (1) WO2022102787A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023352265A1 (en) * 2022-09-30 2025-04-17 Fujifilm Corporation Human astrocyte cell mass, cell mass culture, method for producing human astrocyte cell mass, and method for evaluating test substance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014148646A1 (ja) 2013-03-21 2014-09-25 国立大学法人京都大学 神経分化誘導用の多能性幹細胞
WO2019235576A1 (ja) 2018-06-06 2019-12-12 富士フイルム株式会社 ヒトａ１アストロサイトの製造方法、ヒトａ１アストロサイト、及び被験物質の評価方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014148646A1 (ja) 2013-03-21 2014-09-25 国立大学法人京都大学 神経分化誘導用の多能性幹細胞
WO2019235576A1 (ja) 2018-06-06 2019-12-12 富士フイルム株式会社 ヒトａ１アストロサイトの製造方法、ヒトａ１アストロサイト、及び被験物質の評価方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nature Biotechnology，2019年，Vol. 37, No. 3，pp. 267-275
日本薬理学雑誌，2019年，Vol. 153, No. 2，pp. 54-60

Also Published As

Publication number Publication date
WO2022102787A1 (ja) 2022-05-19
JPWO2022102787A1 (https=) 2022-05-19

Similar Documents

Publication Publication Date Title
US20250019653A1 (en) Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
US20250027054A1 (en) Compositions And Methods For Differentiation Of Human Pluripotent Stem Cells Into Desired Cell Types
US9951353B2 (en) Engineering neural stem cells using homologous recombination
EP2496688B1 (en) A method for differentiation induction in cultured stem cells
US20160215259A1 (en) Method of Preparing Induced Neural Stem Cells Reprogrammed from Non-Neuronal Cells Using HMGA2
JP2007530001A (ja) 希突起膠細胞前駆細胞ならびに希突起膠細胞前駆細胞を得るための方法および培養するための方法
RU2745300C2 (ru) Клетки нервной системы, экспрессирующие e4orf1 аденовируса, и способы их получения и применения
US20190322981A1 (en) Means and methods for the generation of oligodendrocytes
US20150267174A1 (en) Reprogramming peptide and use thereof
JP2004511266A (ja) 間葉間質細胞に対する治療的利用法
WO2018199142A1 (ja) 神経堤細胞および交感神経細胞の製造方法
JP7829230B2 (ja) 多能性幹細胞からアストロサイトを製造する方法
US20240369537A1 (en) In Vitro Cell Co-Cultures of Neuronal Cells, Astrocytes, and Oligodendrocytes
US20240254440A1 (en) Methods to generate glial restricted neural progenitor cells and uses thereof
JP7548494B2 (ja) 細胞の製造方法
JPWO2019078263A1 (ja) 多能性幹細胞から人工神経筋接合部を得る方法
JPWO2017159380A1 (ja) 上位運動ニューロンの誘導方法
US20250276020A1 (en) Dual macroglial-microglial approach towards therapeutic cell replacement in neurodegenerative and neuropsychiatric disease
JP7274216B2 (ja) 細胞興奮毒性評価方法
Qiu et al. Human induced pluripotent stem cell-derived astrocyte and neuron co-culture model for neuroinflammation modeling
Mazzara TWO FACTOR BASED REPROGRAMMING OF FIBROBLASTS AND INDUCED PLURIPOTENT STEM CELLS INTO MYELINOGENIC SCHWANN CELLS
HK40012172A (en) Neural cells expressing adenovirus e4orf1, and methods of making and using the same
Zhang et al. Anindita Sarkar, Salk Institute for Biological Studies, United States Serhiy Forostyak, Charles University, Czechia
Ma Direct Conversion of Astrocytes into Telencephalic Neural Progenitor Cell-like Cells with Defined Transcriptional Factors
HK1236993A1 (en) Neural cells expressing adenovirus e4orf1, and methods of making and using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260224

R150 Certificate of patent or registration of utility model

Ref document number: 7829230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150